|Description:||Rabbit polyclonal antibody to SHP2.|
|Applications:||WB, IHC, FC|
|Immunogen:||A synthetic peptide of human PTPN11|
|Formulation:||PBS with 0.02% sodium azide, 50% glycerol, pH7.3.|
|Synonyms:||BPTP3; CFC; MGC14433; NS1; PTP-1D; PTP2C; SH-PTP2; SH-PTP3; SHP2|
|Background:||PTPN11(protein tyrosine phosphatase, non-receptor type 11) is also named as PTP-1D, PTP2, PTP2C, PTP3, SHP2, CFC, CFC, BPTP3, SH-PTP2, SH-PTP3, MGC14433 and belongs to the protein-tyrosine phosphatase family and non-receptor class 2 subfamily. It modulates and regulates signaling through numerous pathways, many of which are active in the developing endocardial cushions and implicated the ERK pathway as a central mechanism(PMID:19017799). Its signaling may play equally important roles in retinal survival in both physiological and pathological conditions(PMID:21576358). Defects in PTPN11 are the cause of LEOPARD syndrome type 1 (LEOPARD1), Noonan syndrome type 1 (NS1), juvenile myelomonocytic leukemia (JMML) and metachondromatosis (MC). It has 3 isoforms produced by alternative splicing. This antibody is specific to PTPN11.|
|Storage:||Store at 4℃. Avoid freeze / thaw cycles.|
|Recommended Dilutions:||WB 1:500 - 1:2000, IHC 1:50 - 1:100, FC 1:20 - 1:50|
Target (Information from UniProt)
|Function:||Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Dephosphorylates ROCK2 at Tyr-722 resulting in stimulatation of its RhoA binding activity. Dephosphorylates CDC73 (PubMed:26742426).|
|Tissue Specificity:||Widely expressed, with highest levels in heart, brain, and skeletal muscle.|
|Involvement in Disease:||LEOPARD syndrome 1: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.
Noonan syndrome 1: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints.
Leukemia, juvenile myelomonocytic: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.
Metachondromatosis: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest.
|Sequence Similarities:||Belongs to the protein-tyrosine phosphatase family. Non-receptor class 2 subfamily.|
|Post-Translational Modification:||Phosphorylated on Tyr-546 and Tyr-584 upon receptor protein tyrosine kinase activation; which creates a binding site for GRB2 and other SH2-containing proteins. Phosphorylated upon activation of the receptor-type kinase FLT3. Phosphorylated upon activation of the receptor-type kinase PDGFRA (By similarity). Phosphorylated by activated PDGFRB.|
|Cellular Location:||Cytoplasm. Nucleus.|
Western blot analysis of extracts of Jurkat cells lines, using PTPN11 antibody.